PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 24, 2026The Lancet301 citations

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

View Full Paper
MKMikhail KosiborodJDJohn DeanfieldRPRichard Pratley

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kosiborod et al. (2024) studied this question.

synapsesocial.com/papers/6a8c60a9291a21b80a2e4c77https://doi.org/10.1016/s0140-6736(24)01643-x
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes2024 · 705 citations
  2. 2Calculating the number needed to treat for trials where the outcome is time to an event1999 · 726 citations
  3. 3A Novel Paradigm for Heart Failure With Preserved Ejection Fraction2013 · 3,552 citations
  4. 4Spironolactone for Heart Failure with Preserved Ejection Fraction2014 · 2,801 citations
  5. 5Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial2024 · 265 citations